@FiercePharma: Top-read on FP Monday: EU approves GSK's Mekinist and Novartis will reap the rewards. Article | Follow @FiercePharma
@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. Story | Follow @EricPFierce
@CarlyHFierce: ICYMI: Ackman puts forth his slate of new Allergan directors. Report | Follow @CarlyHFierce
> Valeant Pharmaceuticals ($VRX) has completed the $475 million acquisition of PreCision Dermatology. Release
> Robert J. Hombach, currently chief financial officer for Baxter International ($BAX), will become CFO of the unnamed pharmaceutical company that will be created when Baxter next year spins off its biopharma operations. Release
> The FDA has granted priority to review to Purdue Pharma's tamper-resistant competitor to Zohydro, the pain drug for which the FDA has been criticized for approving by those afraid it will be widely abused. Story
> Novartis ($NVS), which is embroiled in a controversy in Japan over the way researchers handled studies, has amended its requirements for clinical trials by outside researchers. Story
> Mylan ($MYL) has launched a generic of Boehringer Ingelheim's hypertension drug Micardis. Story
> Those on both sides of the debate over legalizing marijuana say it is unlikely the FDA, which is evaluating marijuana's place as a Schedule I drug, will downgrade its classification. Story
Medical Device News
@FierceMedDev: ICYMI yesterday: FDA lowers regulatory bar for neurostimulators to treat headache. Story | Follow @FierceMedDev
@StacyALawrence: Boston Scientific backs Israeli cardio device startup Mvalve with $15M. More | Follow @StacyALawrence
@VarunSaxena2: Check out our special report on the top 10 highest paid med tech CEOs. Feature | Follow @VarunSaxena2
@MichaelGFierce: A tiny, "walking" robot powered by a muscle cell? It could help deliver drugs one day. FierceDrugDelivery story | Follow @MichaelGFierce
@EmilyWFierce: Rapid Dx tests for Chagas disease yield quick, reliable results without lab confirmation, according to study. New York Times article | Follow @EmilyWFierce
> Researchers develop realtime, 'nanojuice'-enabled imaging method for gut. Report
> Ulthera device clears FDA for décolleté on heels of Merz acquisition plans. News
> Surgeons tout benefits of Google Glass in operating room. Article
Biotech News
@FierceBiotech: AstraZeneca spreads its virtual reach to cardio R&D with new partnership. News | Follow @FierceBiotech
@JohnCFierce: Intent on closing a deal, AbbVie boosts its bid for Shire to $51B. News | Follow @JohnCFierce
@DamianFierce: So $SHPG has 10 days to consider $ABBV's +11% offer. Press release | Follow @DamianFierce
@EmilyMFierce: European neuroscientists ask for better governance and tough review in EU Human Brain Project. Science story | Follow @EmilyMFierce
> Lilly partners with China's Yabao on diabetes drug. Item
> Boehringer's 'breakthrough' cancer drug comes through in Phase II. Report
> Versant close to capping $300M fund to foster next-gen biotechs. Article
> Novartis' leading CAR-T cancer therapy gains 'breakthrough' status at the FDA. Story
Biotech Research News
> Schizophrenia-linked genetic variation causes abnormal brain cell development. More
> Blocking cell migration could stop cancer spread. Article
> Technique regrows corneas in mice from adult human stem cells. Story
> Chemical switch could be drug target for neurodegenerative disease. More
> AstraZeneca, MRC Technology renew preclinical pact. Item
Pharma Manufacturing News
> Cipla plans U.K. investment as Indian drugmakers await economic reforms. More
> Ingredient price hikes prompt Express Scripts to slash coverage of compounded drugs. Story
> Novo A/S-owned Xellia snaps up Fresenius vial plant to expand in U.S. Report
> Hospira completes Orchid plant takeover to boost API supply security. Item
> Ingredient price hikes prompt Express Scripts to slash coverage of compounded drugs. Story
> Health Canada gives GSK 30 days to show how it will fix its vaccine plant. Article
And Finally... Malaysia's state-owned FELDA plans a $300 million listing on the "life sciences-friendly" Nasdaq as it prepares to bring plant-based drugs to the U.S. Story